MedWatch

Forward Pharma loses European patent case

The European Patent Office has revoked a patent that could have ensured Danish Forward Pharma royalties of US Biogen’s multi-blockbuster Tecfidera. Forward Pharma’s share price declines by almost 30 percent.

Foto: Colourbox

Danish biotech company Forward Pharma lost a long-awaited patent case in Europe. The patent could have brought in significant royalties to the company.

The European Patent Office (EPO) chose to revoke the company’s patent EP2801355 after the oral hearing in the Opposition Proceedings. This is according to a press release from Forward Pharma.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier